Nearly one million children in the USA are potentially misdiagnosed with attention-deficit hyperactivity disorder simply because they are the youngest - and most immature - in their kindergarten class, according to new research by a Michigan State University economist.
These children are significantly more likely than their older classmates to be prescribed behavior-modifying stimulants such as Ritalin (methylphenidate), said Todd Elder, whose study will appear in a forthcoming issue of the Journal of Health Economics.
$320-$500 million unnecessary cost
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze